Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA clears Roche, Lilly Alzheimer's blood tests; Regenxbio gene therapy trial halted by FDA again

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

The FDA has approved Roche and Eli Lilly's Alzheimer's blood tests, marking a significant regulatory advancement in Alzheimer’s diagnostics, while it has again placed a hold on Regenxbio's gene therapy trial due to safety concerns.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a clear opening in Alzheimer's diagnostics as FDA approval lowers barriers to market entry. Watch safety setbacks like Regenxbio’s trial halt closely—they signal increased FDA scrutiny that could delay your gene therapy timelines.

◆ Coverage

1 source · 24 Aug 2026

◆ Related on Wire

◆ Topics

BiotechFDA-clearancealzheimersgene-therapyclinical-trial-holdbiotech-regulation